HAS-BLED Score Calculator for Bleeding Risk Assessment in AF

About

The HAS-BLED bleeding risk score (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol) was developed by Pisters et al. and published in Chest in 2010 using data from 3,978 patients in the Euro Heart Survey on Atrial Fibrillation. The score was specifically designed to assess 1-year risk of major bleeding in patients with atrial fibrillation who are being considered for anticoagulation therapy. It comprises nine clinical variables, each contributing 1 point for a maximum score of 9: uncontrolled hypertension (systolic blood pressure >160 mmHg), abnormal renal function (chronic dialysis, renal transplantation, or serum creatinine >2.6 mg/dL or 200 µmol/L), abnormal liver function (cirrhosis or bilirubin >2 times the upper limit of normal with AST/ALT/ALP >3 times the upper limit of normal), prior stroke (particularly lacunar stroke which is associated with increased bleeding risk), prior major bleeding history or predisposition (anemia, bleeding diathesis), labile international normalized ratio (unstable or high INRs with poor time in therapeutic range <60% for patients on warfarin), elderly age (≥65 years), drug therapy predisposing to bleeding (antiplatelet agents, nonsteroidal anti-inflammatory drugs), and excessive alcohol consumption (≥8 drinks per week). The score performs well for bleeding risk prediction with a c-statistic of approximately 0.72 in the original derivation cohort. It has been externally validated in numerous AF populations and is now recommended by the ESC, AHA/ACC, and NICE guidelines for routine bleeding risk assessment before initiating anticoagulation. Its evidence level is Grade B.

Formula

Hypertension (1) + Abnormal Renal Function (1) + Abnormal Liver Function (1) + Stroke (1) + Bleeding History (1) + Labile INR (1) + Elderly ≥65 (1) + Drugs (1) + Alcohol (1)

The HAS-BLED score is calculated by summing 1 point for each of nine clinical variables present at the time of assessment, yielding a total ranging from 0 to 9. Hypertension is defined as uncontrolled systolic blood pressure >160 mmHg — this differs from the hypertension definition in CHADS-VASc (which uses >140/90 mmHg) and requires active elevation rather than a history of treated hypertension. Abnormal renal function (1 point) encompasses chronic dialysis, renal transplantation, or serum creatinine >2.6 mg/dL (200 µmol/L). Abnormal liver function (1 point) includes cirrhosis or biochemical evidence of significant hepatic impairment (bilirubin >2 times upper limit of normal with transaminases or alkaline phosphatase >3 times upper limit of normal). Prior stroke (1 point) captures the paradoxical observation that patients with prior stroke are at increased risk for both ischemic events AND hemorrhage, particularly cerebral hemorrhage. Bleeding history or predisposition (1 point) includes prior major bleeding (requiring hospitalization or transfusion), anemia (hemoglobin <13 g/dL in men, <12 g/dL in women), or known bleeding diathesis. Labile INR (1 point) applies to patients on warfarin with unstable anticoagulation control (time in therapeutic range [TTR] <60%). Elderly age ≥65 years (1 point) recognizes age as an independent risk factor for bleeding. Drug use (1 point) includes concurrent antiplatelet agents (aspirin, clopidogrel) or NSAIDs that synergistically increase bleeding risk with anticoagulation. Alcohol excess (1 point) is defined as ≥8 standard drinks per week. The score is interpreted dichotomously: a score of 0-2 indicates low bleeding risk (1-year major bleeding rate 1.0-3.7%), while a score of ≥3 indicates high bleeding risk (1-year major bleeding rate 4.0-12.5%). Importantly, a high score should prompt identification and correction of modifiable risk factors (hypertension control, avoidance of NSAIDs, reducing alcohol intake, improving INR control) rather than automatic withholding of anticoagulation.

Score Interpretation

The HAS-BLED score is the most widely validated bleeding risk assessment tool in atrial fibrillation and is recommended by the 2020 ESC Guidelines for atrial fibrillation, the 2024 AHA/ACC Guideline for AF management, and the NICE Guideline NG196 for routine assessment before initiating oral anticoagulation. Its primary clinical impact is not to deny anticoagulation to high-risk patients but rather to guide risk factor modification, inform the choice of anticoagulant, and tailor the intensity of follow-up. The critical message emphasized by all major guidelines is that a high HAS-BLED score (≥3) should NOT lead to withholding of anticoagulation in patients who need it, because the net clinical benefit of stroke prevention with anticoagulation in AF almost uniformly outweighs the bleeding risk. Instead, a high score should trigger a structured approach to identify and address modifiable bleeding risk factors: optimizing blood pressure control (targeting systolic BP <140 mmHg), avoiding unnecessary antiplatelet or NSAID co-prescription, reducing or eliminating alcohol consumption, and improving INR stability with better warfarin management or switching to a DOAC. DOACs have consistently demonstrated lower rates of major bleeding (particularly intracranial hemorrhage) compared to warfarin, and this risk reduction is maintained even in patients with high HAS-BLED scores, making DOACs the preferred choice in this population. The HAS-BLED score has also been validated in DOAC-treated patients, confirming its utility across all anticoagulation strategies. Additionally, the score performs well in predicting major bleeding events beyond gastrointestinal bleeding, including intracranial hemorrhage (c-statistic 0.65-0.70), which carries the highest morbidity and mortality. The HAS-BLED score complements the CHADS-VASc score in what is now regarded as the standard shared decision-making framework for AF management: assess stroke risk with CHADS-VASc, assess bleeding risk with HAS-BLED, and engage the patient in a discussion of individualized risks and benefits.

Reference Ranges